Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11424158 | 1.00 | AKR1B1 (0.39) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL28647875 | 1.00 | AKR1B1 (0.39) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1111426 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL3172348 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2635057 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL23705188 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL28778146 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1170713 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| Hydrochloric Acid SCHEMBL8587069 | 0.85 | LMNA (0.39) | AKR1B1LMNAL3MBTL1TDP1USP2 | |
| Hydrochloric Acid SCHEMBL28634065 | 0.85 | LMNA (0.39) | AKR1B1LMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370555-A1 | METHODS OF PREVENTING PROTEIN AGGREGATION | TrueBinding, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158512-A1 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | TRUEBINDING, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11976279-B2 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | EMORY UNIVERSITY (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4352105-A2 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | TrueBinding, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024073511-A2 | THERAPIES WITH ANTI-GAL3 ANTIBODIES | TRUEBINDING, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-3704262-B1 | MULTIPLEXED ANALYSIS OF MATERIALS FOR TISSUE DELIVERY | GEORGIA TECH RES INST (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4329804-A1 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-113423735-B | Anti-claudin antibodies and uses thereof | 再鼎医药(上海)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-109923123-B | Nanoparticles with molecules that bind or block PD-L1 and their use in the treatment of cancer | 爱默蕾大学 | 2024-01-23 | — | — | CN | disclosed |
| US-20240018526-A1 | DEOXYRIBONUCLEIC ACID-BASED BIOSENSOR AND ASSOCIATED METHODS | FACIBLE BIODIAGNOSTICS LLC (US) | 2024-01-18 | — | — | US | disclosed |
| US-5824473-A | COVALENTLY BONDING TO TRANSITION METAL COMPLEXES; BIOCONDUCTORS AND DIAGNOSTIC PROBES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-10-20 | — | — | US | disclosed |
| US-5780234-A | MODIFIED WITH METAL COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-07-14 | — | — | US | disclosed |
| US-5770369-A | TRANSITION METAL COMPLEXES; DIAGNOSTIC PROBES; HYBRIDIZATION | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-06-23 | — | — | US | disclosed |
| US-5705348-A | COMPLEXING SINGLE STRANDED DNA WITH TRANSITION METAL COMPOUNDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5591578-A | Nucleic acid mediated electron transfer | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996040712-A1 | NUCLEIC ACID MEDIATED ELECTRON TRANSFER | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0172227-A4 | VISION CORRECTION LENS MADE FROM AN AMINOPOLYSACCHARIDE COMPOUND OR AN ETHER OR ESTER THEREOF. | WASHINGTON RES FOUND (US) | 1987-10-20 | — | — | EP | disclosed |
| EP-0172227-A1 | VISION CORRECTION LENS MADE FROM AN AMINOPOLYSACCHARIDE COMPOUND OR AN ETHER OR ESTER THEREOF | Washington Research Foundation (US) | 1986-02-26 | — | — | EP | disclosed |
| WO-1985003716-A1 | VISION CORRECTION LENS MADE FROM AN AMINOPOLYSACCHARIDE COMPOUND OR AN ETHER OR ESTER THEREOF | WASHINGTON RESEARCH FOUNDATION (US) | 1985-08-29 | — | — | WO | disclosed |
| US-4532267-A | Oxygen permeable, wettable lens made of aminoglycan homopolymer | BOARD OF REGENTS, UNIVERSITY OF WASHINGTON (US) | 1985-07-30 | — | — | US | disclosed |